---
figid: PMC9564207__cancers-14-04655-g003
figtitle: 'Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery'
organisms:
- Gallus gallus
- Danio rerio
- Homo sapiens
- Mus musculus
- Caenorhabditis elegans
- Adenoviridae
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
- Gallus gallus
- Drosophila melanogaster
pmcid: PMC9564207
filename: cancers-14-04655-g003.jpg
figlink: /pmc/articles/PMC9564207/figure/cancers-14-04655-f003/
number: F3
caption: 'Molecular mechanisms of JWA in cancer. (A) Genetic susceptibility: JWA can
  act as a biomarker and therapeutic target. Mutations in the JWA promoter region
  (−76G > C) lead to genomic stability and reduce expression of the oncogene JWA,
  thereby increasing the incidence of cancers (leukaemia, oesophageal cancer, gastric
  cancer) in the population. (B) Angiogenesis: JWA inhibits angiogenesis and subsequent
  metastasis in gastric cancer and melanoma by the specific mechanism that JWA ubiquitinates
  and degrades SP1 expression, thus suppressing the transcription of MMP2 and intergrin
  αvβ3. (C) Tumor metastasis: JWA suppresses metastasis involving multiple signaling
  pathways, including inhibition of receptor-dependent (HER2 and CXCR4) PI3K/AKT activation,
  regulation of microfilament depolymerization and reorganization, and inhibition
  of the EMT process. (D) Chemotherapy resistance: in cisplatin-resistant gastric
  cancer cells, JWA is involved in reversing the chemoresistance process by blocking
  the XRCC1-dependent DNA repair pathway and promoting the DR4 receptor-dependent
  apoptosis pathway. (E) Tumor metabolism: JWA enhances cellular oxidative phosphorylation
  and inhibits the glycolytic process through the AMPK/FOXO3a signaling pathway, thereby
  participating in the metabolic reprogramming of cancer cells. (F) Apoptosis: JWA
  promotes cell apoptosis and inhibits cell proliferation in cancer through the mitochondrial
  apoptosis pathway and cell cycle arrest.'
papertitle: 'Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery.'
reftext: Kun Ding, et al. Cancers (Basel). 2022 Oct;14(19):4655.
year: '2022'
doi: 10.3390/cancers14194655
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: JWA | cancer therapy | tumor growth | angiogenesis | metastasis
automl_pathway: 0.8997214
figid_alias: PMC9564207__F3
figtype: Figure
redirect_from: /figures/PMC9564207__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9564207__cancers-14-04655-g003.html
  '@type': Dataset
  description: 'Molecular mechanisms of JWA in cancer. (A) Genetic susceptibility:
    JWA can act as a biomarker and therapeutic target. Mutations in the JWA promoter
    region (−76G > C) lead to genomic stability and reduce expression of the oncogene
    JWA, thereby increasing the incidence of cancers (leukaemia, oesophageal cancer,
    gastric cancer) in the population. (B) Angiogenesis: JWA inhibits angiogenesis
    and subsequent metastasis in gastric cancer and melanoma by the specific mechanism
    that JWA ubiquitinates and degrades SP1 expression, thus suppressing the transcription
    of MMP2 and intergrin αvβ3. (C) Tumor metastasis: JWA suppresses metastasis involving
    multiple signaling pathways, including inhibition of receptor-dependent (HER2
    and CXCR4) PI3K/AKT activation, regulation of microfilament depolymerization and
    reorganization, and inhibition of the EMT process. (D) Chemotherapy resistance:
    in cisplatin-resistant gastric cancer cells, JWA is involved in reversing the
    chemoresistance process by blocking the XRCC1-dependent DNA repair pathway and
    promoting the DR4 receptor-dependent apoptosis pathway. (E) Tumor metabolism:
    JWA enhances cellular oxidative phosphorylation and inhibits the glycolytic process
    through the AMPK/FOXO3a signaling pathway, thereby participating in the metabolic
    reprogramming of cancer cells. (F) Apoptosis: JWA promotes cell apoptosis and
    inhibits cell proliferation in cancer through the mitochondrial apoptosis pathway
    and cell cycle arrest.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ti
  - Akt1
  - Pik3r1
  - Gc
  - Cdk12
  - Bcl2
  - Erbb2
  - Cxcr2
  - Sp1
  - Marchf8
  - Csnk2a1
  - Csnk2a2
  - Xrcc1
  - Uqcrc2
  - Mmp2
  - Prkdc
  - Tnfsf10
  - Bax
  - Nkx3-1
  - Itk
  - Slc22a3
  - .na.character
  - Ptk2
  - ARL6IP5
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - GC
  - CDK12
  - CDK1
  - CDK2
  - BCL2
  - ERBB2
  - CXCR2
  - SP1
  - PSG1
  - DAND5
  - MARCHF8
  - CSNK2A1
  - CSNK2A2
  - CSNK2B
  - HLA-DRB4
  - TNFRSF10A
  - XRCC1
  - UQCRC2
  - MMP2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - PRKDC
  - TNFSF10
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - BAX
  - ITK
  - SLC22A3
  - PTK2
  - gc
  - cdk12
  - bcl2a
  - her2
  - cxcr2
  - sp1
  - marchf8
  - olfck3
  - olfck2
  - xrcc1
  - uqcrc2b
  - mmp2
  - baxa
  - ptk2ab
  - CXCR1
  - TRAIL-LIKE
  - Jwa
  - Cds
  - cd-s
  - lush
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - SNF4Agamma
  - AMPKalpha
  - Crtc
  - Debcl
  - grass
  - Spn42Dd
  - CkIIbeta
  - CkIIbeta2
  - CkIIalpha
  - CycE
  - cyc
  - UQCR-C2
  - MKP-4
  - p38b
  - rl
  - oo
  - LanB2
  - anon-70Db
  - Low
  - Fak
---
